Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nephros Inc (NEPH)

Nephros Inc (NEPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,154
  • Shares Outstanding, K 10,319
  • Annual Sales, $ 10,400 K
  • Annual Income, $ -4,110 K
  • 60-Month Beta 1.23
  • Price/Sales 2.00
  • Price/Cash Flow N/A
  • Price/Book 1.55
Trade NEPH with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +13.51%
on 05/12/22
4.65 -51.16%
on 04/19/22
-2.25 (-49.78%)
since 04/13/22
3-Month
2.00 +13.51%
on 05/12/22
5.00 -54.60%
on 03/29/22
-2.53 (-52.71%)
since 02/16/22
52-Week
2.00 +13.51%
on 05/12/22
11.67 -80.54%
on 06/29/21
-5.38 (-70.33%)
since 05/14/21

Most Recent Stories

More News
Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of -53.85% and 25.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

NEPH : 2.27 (+10.73%)
VIVO : 24.63 (-0.16%)
Nephros Announces Results for Quarter Ended March 31, 2022

First Quarter Net Revenue of $2.2 Million;Active Customer Sites Climb 17% to New Record SOUTH ORANGE, NJ, May 04, 2022 (GLOBE NEWSWIRE) -- via...

NEPH : 2.27 (+10.73%)
Nephros First Quarter 2022 Financial Results Conference Call

SOUTH ORANGE, NJ, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing...

NEPH : 2.27 (+10.73%)
Nephros Unveils New Branding and Website

Rebrand reflects an integrated approach to water safety, with expanded focus on customer solutions and educational resources  SOUTH ORANGE, NJ,...

NEPH : 2.27 (+10.73%)
Nephros to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

SOUTH ORANGE, NJ, March 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing...

NEPH : 2.27 (+10.73%)
Nephros Inc. (NEPH) Reports Q4 Loss, Misses Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of -10% and 1.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NEPH : 2.27 (+10.73%)
EOLS : 13.72 (+4.10%)
Nephros Announces Fourth Quarter and Fiscal Year 2021 Financial Results

Reports Full-Year Net Revenue of $10.4 Million, a 22% Year-Over-Year Increase and Fourth Quarter Net Revenue of $2.8 Million, an 18% Year-Over-Year...

NEPH : 2.27 (+10.73%)
Nephros Fourth Quarter 2021 Financial Results Conference Call

SOUTH ORANGE, NJ, Feb. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing...

NEPH : 2.27 (+10.73%)
RION Appoints Alisa Lask as Chief Commercial Officer

RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief...

CLGN : 8.56 (+5.03%)
NEPH : 2.27 (+10.73%)
Nephros Issues 2022 Shareholder Letter

SOUTH ORANGE, NJ, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing...

NEPH : 2.27 (+10.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider.

See More

Key Turning Points

3rd Resistance Point 2.65
2nd Resistance Point 2.54
1st Resistance Point 2.41
Last Price 2.27
1st Support Level 2.17
2nd Support Level 2.06
3rd Support Level 1.93

See More

52-Week High 11.67
Fibonacci 61.8% 7.97
Fibonacci 50% 6.83
Fibonacci 38.2% 5.69
Last Price 2.27
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar